#lylam - Twitter Hashtag

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC

about 3 years ago

Our Center for Blood Cancers awards pilot funding to two multidisciplinary research teams investigating therapeutic approaches for acute lymphoblastic and acute myeloid #leukemia. @DrKrogsgaard @Dr_Shella_SF For more on these #lylal and #lylam studies: https://t.co/6OwzqJzQKv

Perlmutter_CC's tweet photo. Our Center for Blood Cancers awards pilot funding to two multidisciplinary research teams investigating therapeutic approaches for acute lymphoblastic and acute myeloid #leukemia. @DrKrogsgaard @Dr_Shella_SF

For more on these #lylal and #lylam studies: https://t.co/6OwzqJzQKv https://t.co/nr4sYxGuN6

0

4

3

0

540

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC

about 3 years ago

Round of applause PCC's Center for Blood Cancer pilot proposal funding awardee, “Evaluation of Phosphopeptide Neoantigens as Immunotherapy Targets for Acute Myeloid Leukemia” #lysm #lylam 👏 👏Dr. Krogsgaard @DrKrogsgaard, Dr. Abdul Hay, and Dr. Patskovsky.

Perlmutter_CC's tweet photo. Round of applause PCC's Center for Blood Cancer pilot proposal funding awardee, “Evaluation of Phosphopeptide Neoantigens as Immunotherapy Targets for Acute Myeloid Leukemia” #lysm #lylam

👏 👏Dr. Krogsgaard @DrKrogsgaard, Dr. Abdul Hay, and Dr. Patskovsky. https://t.co/QmgBlJtzZN

0

3

1

0

811

Oncology Times @OncologyTimes

about 4 years ago

Researchers at @OhioState believe that dramatic differences in pretreatment molecular genetic profiles of Black and white patients living with #AML may partially explain discrepancies found between the survival rates of each group #lylam: https://t.co/eOI7dPFwA7

OncologyTimes's tweet photo. Researchers at @OhioState believe that dramatic differences in pretreatment molecular genetic profiles of Black and white patients living with #AML may partially explain discrepancies found between the survival rates of each group #lylam: https://t.co/eOI7dPFwA7 https://t.co/9F18hSq6iU

0

3

1

0

OncLive SOSS @OncLiveSOSS

almost 7 years ago

Next up, we met with Eytan M. Stein, MD, of @sloan_kettering. Dr. Stein gave an overview on the many exciting updates in AML, as well as the challenges the field is still facing. Thank you for your interview! #lylam #stateofscience

OncLiveSOSS's tweet photo. Next up, we met with Eytan M. Stein, MD, of @sloan_kettering. Dr. Stein gave an overview on the many exciting updates in AML, as well as the challenges the field is still facing. Thank you for your interview! #lylam #stateofscience https://t.co/ndAcoEuEqq

0

8

1

0

CancerCare @CancerCare

almost 7 years ago

@KNOW_AML is raising awareness about acute myeloid leukemia during Blood Cancer Awareness Month! Learn more about their campaign and how you can join: https://t.co/u8nJiUDXtC #bloodcancer #aml #luesm #lylam #leukemia

CancerCare's tweet photo. @KNOW_AML is raising awareness about acute myeloid leukemia during Blood Cancer Awareness Month! Learn more about their campaign and how you can join: https://t.co/u8nJiUDXtC #bloodcancer #aml #luesm #lylam #leukemia https://t.co/86m379RO49

0

4

2

0

CancerCare @CancerCare

almost 7 years ago

September is Blood Cancer Awareness Month and @KNOW_AML is raising awareness about acute myeloid leukemia. Learn more about their campaign and how you can help: https://t.co/b12wAyj4dc #bloodcancer #aml #luesm #lylam #leukemia

CancerCare's tweet photo. September is Blood Cancer Awareness Month and @KNOW_AML is raising awareness about acute myeloid leukemia. Learn more about their campaign and how you can help: https://t.co/b12wAyj4dc #bloodcancer #aml #luesm #lylam #leukemia https://t.co/2jcly6PWYi

0

5

4

0

OncLive.com

@OncLive

about 7 years ago

WATCH: FDA Approvals in SCLC and of a Biosimilar, and Japanese Approvals in AML, Ovarian Cancer, and NTRK+ Tumors #lcsmc #lylam #ovca https://t.co/JTzf0j31Tm

0

1

0

OncLive SOSS @OncLiveSOSS

over 8 years ago

Venetoclax shows very high response rates when used in combination with a hypomethylating agent in patients with newly diagnosed AML, says William B. Donnellan, MD, of @SarahCannonDocs #lylam https://t.co/5t2qd9Guis

0

2

1

0